文献速递银屑病与炎症性皮肤病

银屑病与代谢综合征相关性的系统评价与荟萃分析

Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome.
PubMed 文献 · J Am Acad Dermatol · 2017-01-01

该研究系统检索MEDLINE、Scopus、SciELO、Google Scholar、Science Direct和LILACS截至2016年1月的观察性研究,纳入14篇论文共25,042例银屑病患者,对报告校正比值比(OR)及95%CI的研究行随机效应模型荟萃分析。结果显示银屑病患者中代谢综合征患病率为31.4%(OR 1.42,95%CI 1.28-1.65),中东地区研究OR为1.76(95%CI 0.86-2.67),欧洲研究OR为1.40(95%CI 1.25-1.55)。作者建议临床医生考虑对银屑病患者筛查代谢危险因素。

要点

  • 银屑病患者代谢综合征患病率为31.4%,合并OR为1.42(95%CI 1.28-1.65)。
  • 中东地区研究OR 1.76(95%CI 0.86-2.67),欧洲研究OR 1.40(95%CI 1.25-1.55)。
  • 建议临床医生对银屑病患者筛查代谢危险因素。

核心结论

  • 银屑病与代谢综合征存在关联,合并OR为1.42(95%CI 1.28-1.65),因风险增加建议筛查代谢危险因素。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Scopus、SciELO、Google Scholar、Science Direct和LILACS截至2016年1月。
  • 纳入14篇观察性研究,共25,042例成人银屑病患者,对报告校正OR及95%CI的研究行随机效应模型荟萃分析。
  • 亚组分析涉及地理位置、诊断标准和偏倚风险。

主要发现

  • 银屑病患者中代谢综合征患病率为31.4%(OR 1.42,95%CI 1.28-1.65)。
  • 中东地区研究(以色列、土耳其、黎巴嫩)OR为1.76(95%CI 0.86-2.67),高于欧洲研究(德国、意大利、英国、挪威、丹麦)OR 1.40(95%CI 1.25-1.55)。

关键数值与推荐

  • 代谢综合征在银屑病患者中的合并OR为1.42(95%CI 1.28-1.65)。
  • 中东地区研究OR 1.76(95%CI 0.86-2.67),欧洲研究OR 1.40(95%CI 1.25-1.55)。

临床怎么用

  • 临床医生应考虑对银屑病患者筛查代谢危险因素。

局限性

  • 校正混杂因素的可用研究较少,且各文献间存在不一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have shown a relationship between psoriasis and metabolic syndrome (MS), but no meta-analysis has been restricted to studies that adjusted for confounders. OBJECTIVE: To determine the association between psoriasis and MS. METHODS: A systematic review and meta-analysis of observational studies on psoriasis and MS in adults was performed from MEDLINE, Scopus, SciELO, Google Scholar, Science Direct, and LILACS from inception to January 2016. We performed a random effects model meta-analysis for those studies reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). The subgroup analysis was related to geographic location, diagnosis criteria and risk of bias. RESULTS: In all, 14 papers including a total of 25,042 patients with psoriasis were analyzed. We found that MS was present in 31.4% of patients with psoriasis (OR, 1.42; 95% CI, 1.28-1.65). Middle Eastern studies (in Israel, Turkey, and Lebanon) (OR, 1.76, 95% CI, 0.86-2.67) reported a greater risk for MS than European studies (in Germany, Italy, the United Kingdom, Norway, and Denmark) (OR, 1.40; 95% CI, 1.25-1.55). LIMITATIONS: Few adjusted studies existed, and there was inconsistency between publications. CONCLUSION: Because of the increased risk for MS, clinicians should consider screening patients with psoriasis for metabolic risk factors.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017. PMID: 28917453. doi:10.1016/j.jaad.2017.04.1133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。